Investment case
Alnylam Pharmaceuticals, Inc.
ALNY · 13 developments mapped · last assessed 2026-09-25
Market Ontology has mapped 13 macro, policy, and market developments to Alnylam Pharmaceuticals, Inc. since 2026-08-26. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ALNY yet, so no modelled value is shown. The ALNY valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ALNY on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
Similar to Moderna, Alnylam is a leader in RNA interference (RNAi) therapeutics. ADARx's successful IPO in the RNA-targeting space could signal increased investor confidence and capital availability for companies developing similar technologies.
· Moves sector specific sentiment, future pipeline valuation
- Open question
Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
Potential for increased competition or partnership opportunities in RNAi-based therapies for neurological disorders.
· Moves pipeline valuation, market size estimates
What changed, by assumption
- 2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
- 2026-09-24Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs
- 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share
- 2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-25 | ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share | mixed | 3-12m | 0.20 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share | watch | 1-3m | 0.20 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17 | Bullish | 1-3m | 0.40 |
| 2026-09-25 | ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share | watch | 1-3m | 0.30 |
| 2026-09-24 | Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease | watch | 3-12m | 0.20 |
| 2026-09-24 | Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease | watch | 3-12m | 0.30 |
| 2026-09-24 | Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD | watch | 3-12m | 0.30 |
| 2026-09-24 | Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies | watch | 3-12m | 0.20 |
| 2026-09-24 | Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs | Bullish | 1-3m | 0.40 |
| 2026-09-24 | Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin | watch | 3-12m | 0.20 |
| 2026-09-23 | Roche to Acquire Ionis Pharmaceuticals, Inc. | watch | 3-12m | 0.30 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | watch | 1-3m | 0.20 |